The role of catheter ablation for ventricular tachycardia in patients with ischemic heart disease

Current Opinion in Cardiology

Volumn 26, Issue 1, 2011, Pages 30-39

  El Damaty, Ahmed ^a   Sapp Jr , John L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antiarrhythmic drug therapy; Catheter ablation; Ischemic heart disease; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOFETILIDE; DRONEDARONE; SOTALOL;

ARTICLE; BRADYCARDIA; BRAIN EMBOLISM; CATHETER ABLATION; COMPARATIVE STUDY; COMPLETE HEART BLOCK; DEATH; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; LUNG DISEASE; LUNG INFILTRATE; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; CATHETER ABLATION; HUMANS; MYOCARDIAL ISCHEMIA; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 79951669628     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328341390b     Document Type: Article

References (73)

1. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 9:445-451. (Pubitemid 23222329)
2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297-1302. (Pubitemid 30158618)
3. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576-1583.
4. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350-e408.
5. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study - a randomized trial. JAMA 2006; 295:165-171. (Pubitemid 43076435)
6. Credner SC, Klingenheben T, Mauss O, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32:1909-1915. (Pubitemid 29010454)
7. Pedersen SS, Sears SF, Burg MM, et al. Does ICD indication affect quality of life and levels of distress? Pacing Clin Electrophysiol 2009; 32:153-156.
8. Pedersen SS, Theuns DA, Erdman RA, et al. Clustering of device-related concerns and type D personality predicts increased distress in ICD patients independent of shocks. Pacing Clin Electrophysiol 2008; 31:20-27.
9. Pedersen SS, van Domburg RT, Theuns DA, et al. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks. Am Heart J 2005; 149:664-669.
10. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002; 144:282-289. (Pubitemid 34879652)
11. El-Damaty AM, Sapp JL, Basta MN, et al. Inappropriate ICD shocks: clinical risk factors and mortality. Heart Rhythm 2010; 7 (5S):S186.
12. Abdelwahab AM, MacIntyre CJ, Parkash R, et al. Predictors of mortality after ICD shocks. Can J Cardiol 2007; 23 (Suppl C):191C.
13. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357-1365. (Pubitemid 351443082)
14. Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation 2006; 113:2810-2817. (Pubitemid 44305293)
15. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009-1017.
16. Sweeney MO, Sherfesee L, DeGroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010; 7:353-360.
17. Pacifico A, Ferlic LL, Cedillo-Salazar FR, et al. Shocks as predictors of survival in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 1999; 34:204-210.
18. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110:3760-3765. (Pubitemid 40023973)
19. Raitt MH. Implantable cardioverter-defibrillator shocks: a double-edged sword? J Am Coll Cardiol 2008; 51:1366-1368.
20. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009; 6:886-933.
21. Akiyama J, Aonuma K, Nogami A, et al. Thrombolytic therapy can reduce the arrhythmogenic substrate after acute myocardial infarction: a study using the signal-averaged electrocardiogram, endocardial catheter mapping and programmed ventricular stimulation. Jpn Circ J 1999; 63:838-842. (Pubitemid 29535712)
22. Chong JJ, Ganesan AN, Eipper V, et al. Comparison of left ventricular ejection fraction and inducible ventricular tachycardia in ST-elevation myocardial infarction treated by primary angioplasty versus thrombolysis. Am J Cardiol 2008; 101:153-157.
23. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantabledefibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855-1862.
24. Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004; 110:3646-3654. (Pubitemid 39665252)
25. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996; 348:7-12. (Pubitemid 26237238)
26. Brendorp B, Pedersen O, Torp-Pedersen C, et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 2002; 25:847-865. (Pubitemid 35178643)
27. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791-798.
28. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year followup of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004; 110:112-116. (Pubitemid 38924577)
29. Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109:990-996. (Pubitemid 38282852)
30. Pratt CM, Al-Khalidi HR, Brum JM, et al. Cumulative experience of azimilideassociated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol 2006; 48:471-477. (Pubitemid 44109955)
31. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
32. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406-412.
33. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol 1997; 20:704-710.
34. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857-865. (Pubitemid 29427047)
35. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687. (Pubitemid 351860860)
36. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol 2004; 15:52-58. (Pubitemid 38147219)
37. Das MK, Scott LR, Miller JM. Focal mechanism of ventricular tachycardia in coronary artery disease. Heart Rhythm 2010; 7:305-311.
38. de Bakker J, van Capelle F, Janse M, et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation 1993; 88:915-926. (Pubitemid 23264006)
39. de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 1990; 15:1594-1607. (Pubitemid 20174323)
40. de Bakker JM, van Capelle FJL, Janse JM, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlates. Circulation 1988; 77:589-606. (Pubitemid 18073351)
41. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004; 84:431-488. (Pubitemid 38365490)
42. Camelliti P, Green CR, Kohl P. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv Cardiol 2006; 42:132-149. (Pubitemid 43805861)
43. Morady F, Harvey M, Kalbfleisch SJ, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation 1993; 87:363-372. (Pubitemid 23040904)
44. Gonska BD, Cao K, Schaumann A, et al. Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: results and longterm follow-up. J Am Coll Cardiol 1994; 24:1506-1514. (Pubitemid 24344247)
45. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997; 96:1525-1531. (Pubitemid 27375347)
46. Stevenson WG, Friedman PL, Kocovic D, et al. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation 1998; 98:308-314. (Pubitemid 28348052)
47. O'Callaghan PA, Poloniecki J, Sosa-Suarez G, et al. Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Cardiol 2001; 87:975-979. (Pubitemid 32299982)
48. Della Bella P, Riva S, Fassini G, et al. Incidence and significance of pleomorphism in patients with postmyocardial infarction ventricular tachycardia. Acute and long-term outcome of radiofrequency catheter ablation. Eur Heart J 2004; 25:1127-1138. (Pubitemid 38834071)
49. Bogun F, Kim HM, Han J, et al. Comparison of mapping criteria for hemodynamically tolerated, postinfarction ventricular tachycardia. Heart Rhythm 2006; 3:20-26. (Pubitemid 43071884)
50. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000; 35:1905-1914. (Pubitemid 30342874)
51. Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation 2001; 104:664-669. (Pubitemid 32738520)
52. Sra J, Bhatia A, Dhala A, et al. Electroanatomically guided catheter ablation of ventricular tachycardias causing multiple defibrillator shocks. Pacing Clin Electrophysiol 2001; 24:1645-1652. (Pubitemid 33065524)
53. de Chillou C, Lacroix D, Klug D, et al. Isthmus characteristics of reentrant ventricular tachycardia after myocardial infarction. Circulation 2002; 105:726-731. (Pubitemid 34157377)
54. Borger van der Burg AE, de Groot NM, van Erven L, et al. Long-term follow-up after radiofrequency catheter ablation of ventricular tachycardia: a successful approach? J Cardiovasc Electrophysiol 2002; 13:417-423. (Pubitemid 34494258)
55. Arenal A, del Castillo S, Gonzalez-Torrecilla E, et al. Tachycardia-related channel in the scar tissue in patients with sustained monomorphic ventricular tachycardias: influence of the voltage scar definition. Circulation 2004; 110:2568-2574. (Pubitemid 39453003)
56. Segal OR, Chow AW, Markides V, et al. Long-term results after ablation of infarct-related ventricular tachycardia. Heart Rhythm 2005; 2:474-482. (Pubitemid 40521359)
57. Deneke T, Grewe PH, Lawo T, et al. Substrate-modification using electroanatomical mapping in sinus rhythm to treat ventricular tachycardia in patients with ischemic cardiomyopathy. Z Kardiol 2005; 94:453-460. (Pubitemid 40956672)
58. Klemm HU, Ventura R, Steven D, et al. Catheter ablation of multiple ventricular tachycardias after myocardial infarction guided by combined contact and noncontact mapping. Circulation 2007; 115:2697-2704. (Pubitemid 46842785)
59. Deneke T, Lawo T, Grewe PH, et al. Usefulness of a limited linear ablation of post-myocardial infarction ventricular tachycardia using a standardized approach based on sinus rhythm mapping. Am J Cardiol 2010; 105:1235-1239.
60. Kottkamp H, Wetzel U, Schirdewahn P, et al. Catheter ablation of ventricular tachycardia in remote myocardial infarction: substrate description guiding placement of individual linear lesions targeting noninducibility. J Cardiovasc Electrophysiol 2003; 14:675-681. (Pubitemid 36843082)
61. Kautzner J, Cihak R, Peichl P, et al. Catheter ablation of ventricular tachycardia following myocardial infarction using three-dimensional electroanatomical mapping. Pacing Clin Electrophysiol 2003; 26:342-347. (Pubitemid 36399169)
62. Reddy VY, Neuzil P, Taborsky M, et al. Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-irrigated catheter. J Am Coll Cardiol 2003; 41:2228-2236. (Pubitemid 36724273)
63. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657-2665.
64. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverterdefibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462-469.
65. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the Multicenter Thermocool Ventricular Tachycardia Ablation Trial. Circulation 2008; 118:2773-2782.
66. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375:31-40.
67. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scarrelated ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 21:47-53.
68. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter- defibrillators. Short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462-469.
69. Estes NA 3rd. Ablation after ICD implantation: bridging the gap between promise and practice. N Engl J Med 2007; 357:2717-2719.
70. Kuck KH. VTACH trial: authors' reply. Lancet 2010; 375:890-891.
71. Stevenson WG, Tedrow U. Preventing ventricular tachycardia with catheter ablation. Lancet 2010; 375:4-6.
72. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-754. (Pubitemid 30648765)
73. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993; 72:280-287.